Aki Matsushima

This inventor holds 5 USPTO granted patents, plus 1 CIPO patent and 2 EPO patents. Top assignee: Kyowa Hakko Kirin Co., Limited. Active years: 2015-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Aki Matsushima. Retrieved from https://idiyas.com/inventor/aki-matsushima

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 5

% Patents Active = 40.0

CIPO Patents = 1

EPO Patents = 2 (Patent Applications = 2)

Average Co-Inventor Count = 3.5

ph-index = 3

Forward Citations = 20(Granted Patents)

Location History:

Toyko, JP (2015)
Tokyo, JP (2015 - 2017)
Shizuoka, JP (2016 - 2017)

Company Filing History:

5 out of 272

Kyowa Hakko Kirin Co., Limited

patents

Years Active: 2015-2017

Loading Chart...

5 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9598494 - Anti-CD40 antibody mutants (2017-03-21),

2. 9587031 - DNA encoding an anti-CD40 IgG2 antibody having amino acid mutations (2017-03-07),

3. 9234044 - Agonistic anti-CD40 IGG2 antibodies having amino acid mutations introduced therein (2016-01-12),

4. 9023361 - Methods for treating transplant rejection by administering anti-CD40 antibody (2015-05-05),

5. 9023360 - Methods of treating autoimmune disease with anti-CD40 antibodies (2015-05-05),

Title: Aki Matsushima - Innovator in Antibody Therapeutics

Introduction

Aki Matsushima is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of antibody therapeutics, holding a total of five patents. His work focuses on optimizing anti-CD40 antibodies for pharmaceutical applications.

Latest Patents

Matsushima's latest patents include innovative mutants of anti-CD40 antibodies designed to reduce antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) activities. These mutants are optimized for therapeutic use, featuring modifications in the constant region to enhance their efficacy as pharmaceutical agents. One notable invention involves a monoclonal antibody with specific amino acid substitutions that enhance its agonistic activity while binding effectively to human CD40.

Career Highlights

Aki Matsushima is affiliated with Kyowa Hakko Kirin Co., Limited, a leading biopharmaceutical company. His research and inventions have positioned him as a key figure in the development of novel therapeutic agents targeting immune responses.

Collaborations

Throughout his career, Matsushima has collaborated with esteemed colleagues, including Nobuaki Takahashi and Toru Miura. These partnerships have fostered a collaborative environment that enhances innovation and research in antibody development.

Conclusion

Aki Matsushima's contributions to the field of antibody therapeutics exemplify his dedication to advancing medical science. His

Profile summary based on public USPTO records.